Related Experiment Video
Updated: May 1, 2026

Affordable Oxygen Microscopy-Assisted Biofabrication of Multicellular Spheroids
Published on: April 6, 2022
Shaping Dendrimers for Active Oxygen Delivery: An Emerging Strategy for Targeting Tumor Microenvironments
1Faculty of Pharmacy, Middle East University, 11610 Amman, Jordan.
Abstract:
Reactive oxygen species (ROS) have been identified as one of the critical factors in cancer development. ROS have been linked to cancer at all stages, and their applications in cancer treatment have gained attention due to their concentration-dependent implications: (1) low to moderate levels as fundamental signaling molecules, and (2) higher levels in cancer cells as a unique characteristic of cancer and cytotoxic agents. However, resistance and off-target effects are the main barriers that can hinder and limit the therapeutic efficacy of chemotherapies. The main reason for that is the complex tumor microenvironment such as hypoxia. Developing drug nanocarriers that can target ROS represents a potential delivery platform to overcome these barriers. For instance, doxorubicin-encapsulated ROS (nitric oxide) micelles accumulated 6.7-fold more drug in PC3-Luc cancer cells than when using this drug alone. Regrettably, the past studies have merely discussed the micelle alone as a nanocarrier for the delivery of ROS-based therapy in cancer without exploring dendrimers. Instead, this review examines the structural design of dendrimers tailored for oxygen transport, their conjugation with ROS-generating therapies, and therapeutic applications in photodynamic therapy, radiotherapy, and chemotherapy. Besides, it also discusses the translational challenges and future perspectives for ROS-based dendrimers. For the first time, this work also critically compares various dendrimer types and generations, oxygen-delivery strategies, drug loading properties, in vitro/in vivo outcomes, and toxicity data. A dedicated section discussing biodistribution, clearance, biocompatibility, and regulatory considerations of dendrimers was also explored in this study. Finally, this review concludes that the dendrimers can be engineered to carry and deliver active oxygen by using the following delivery strategies: (1) addition of oxygen carriers, (2) enzyme functionalization, (3) the incorporation of photosensitizers and metal ions, and (4) surface alterations.
Insights
Dendrimers can be engineered to deliver oxygen and reactive oxygen species (ROS) for cancer treatment, overcoming drug resistance and off-target effects. This review explores their design, applications, and future potential in cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Reactive oxygen species (ROS) play a dual role in cancer, acting as signaling molecules at low levels and cytotoxic agents at high levels.
- Chemotherapy faces challenges like drug resistance and off-target effects, often exacerbated by the tumor microenvironment (e.g., hypoxia).
- Nanocarriers targeting ROS offer a promising strategy to enhance cancer therapy efficacy.
Purpose of the Study:
- To review the structural design of dendrimers for oxygen transport and conjugation with ROS-generating therapies.
- To explore the therapeutic applications of ROS-based dendrimers in photodynamic therapy, radiotherapy, and chemotherapy.
- To critically compare different dendrimer types, oxygen delivery strategies, drug loading, and outcomes, while discussing translational challenges.
Main Methods:
- Review of existing literature on dendrimers for ROS-based cancer therapy.
- Analysis of structural designs for oxygen transport and ROS conjugation.
- Comparison of various dendrimer types, generations, and delivery strategies.
- Evaluation of in vitro/in vivo outcomes, toxicity, biodistribution, and regulatory aspects.
Main Results:
- Dendrimers can be engineered for oxygen transport and ROS delivery using strategies like oxygen carriers, enzyme functionalization, photosensitizers, metal ions, and surface modifications.
- Previous studies primarily focused on micelles, neglecting the potential of dendrimers in ROS-based cancer nanomedicine.
- This review provides a comprehensive comparison of dendrimer types, delivery methods, and therapeutic outcomes.
Conclusions:
- Dendrimers represent a versatile platform for developing targeted ROS-based cancer therapies.
- Engineered dendrimers can overcome limitations of conventional chemotherapy by addressing tumor hypoxia and improving drug delivery.
- Further research into biodistribution, biocompatibility, and regulatory pathways is crucial for clinical translation.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
09:01Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Modified-Release Drug Delivery Systems: Site-Targeted
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...